EXCLUSIVE: SAB Biotherapeutics Says Diabetes Immunotherapy Shows Therapeutic Effect In Toxicology Study
Portfolio Pulse from Vandana Singh
SAB Biotherapeutics announced positive safety and pharmacologic data from a GLP toxicology study for SAB-142, a Type 1 Diabetes immunotherapy. The study met its primary objective, and the company plans to submit an IND application and initiate a Phase 1 trial in the next few months.
June 21, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SAB Biotherapeutics' SAB-142 immunotherapy shows positive results in a toxicology study, potentially leading to an IND application and Phase 1 trial initiation.
The positive results from the toxicology study indicate that SAB-142 has a similar mechanism of action to FDA-approved anti-thymocyte rabbit globulin (ATG) and has met its primary objective. This increases the likelihood of SAB Biotherapeutics submitting an IND application and initiating a Phase 1 trial in the next few months, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100